We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Genetic Mutation Test Improves Definitive Diagnosis of Thyroid Nodules

By LabMedica International staff writers
Posted on 03 Jun 2015
Cytopathology on ultrasound-guided fine needle aspiration biopsies has dramatically improved the clinical management of patients with solid thyroid nodules that are greater than one centimeter. More...


Molecular testing for oncogenic mutations or gene expression in fine-needle aspirations (FNA) from thyroid nodules with indeterminate cytology identified a subset of benign or malignant lesions with high predictive value.

Several scientists working at various institutions including Jersey Shore University Medical Center (Neptune City, NJ, USA) evaluated a novel diagnostic algorithm combining mutation detection and micro-ribonucleic acid (miRNA) expression to improve the diagnostic yield of molecular cytology. The teams tested 638 surgical specimens and preoperative FNAs for 17 validated gene alterations using a commercial thyroid test and with a 10-miRNA gene expression classifier generating positive (malignant) or negative (benign) results. Qualitative molecular results were compared to surgical histopathology to determine diagnostic performance and model clinical impact.

The miRInform Thyroid test (Asuragen Inc.; Austin, TX, USA) detected mutations in 69% of nodules with malignant outcome. Among mutation-negative specimens, miRNA testing correctly identified 64% of malignant cases and 98% of benign cases. The diagnostic sensitivity and specificity of the combined algorithm was 89% and 85%, respectively. At 32% cancer prevalence, 61% of the molecular results were benign with a negative predictive value of 94%. Independently of variations in cancer prevalence, the test increased the yield of true benign results by 65% relative to messenger (mRNA)-based gene expression classification and decreased the rate of avoidable diagnostic surgeries by 69%.

The authors including those from Asuragen, Inc., concluded that multiplatform testing for DNA, mRNA and miRNA can accurately classify benign and malignant thyroid nodules, increase the diagnostic yield of molecular cytology, and further improve the preoperative risk-based management of benign nodules. The study was published on May 12, 2015, in the Journal of Clinical Endocrinology & Metabolism.

Related Links:

Jersey Shore University Medical Center
Asuragen Inc.



New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Rapid Test Reader
DIA5000
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.